Top 70+ Pharmaceutical Companies In NJ In 2021
← Visit blog

Top 70+ Pharmaceutical Companies In NJ In 2021

Updated on March 8th, 2021

Top 70+ Pharmaceutical Companies In NJ In 2021

A hand curated list of 70+ top pharmaceutical companies in NJ.
Whether you run a digital agency, a B2B company, or just want to connect with fast growing companies, this is the list for you.
In our premium lists, we also include: • 20+ data points for each company
• Services they’re likely to outsource
• CEO Information & Email
If you’re interested in our premium lists, consider subscribing to our monthly report of tech companies.


Table Of Contents

  1. Prolong Pharmaceuticals ($1M to $10M)
  2. Leading Pharma ($1M to $10M)
  3. Aquestive Therapeutics ($10M to $50M)
  4. Derma Sciences ($50M to $100M)
  5. Prokaryotics (Less than $1M)
  6. DiRx Health (Less than $1M)
  7. RespireRx Phamaceuticals (Less than $1M)
  8. TAXIS Pharmaceuticals (Less than $1M)
  9. BodyBio ($10M to $50M)
  10. Elite Pharmaceuticals ($1M to $10M)
  11. Outlook Therapeutics ($1M to $10M)
  12. Protalex (Less than $1M)
  13. Amerigen Pharmaceuticals ($1M to $10M)
  14. Vascular Therapies ($1M to $10M)
  15. Provention Bio ($500M to $1B)
  16. KBP Biosciences ($1M to $10M)
  17. Welmedix Consumer Healthcare ($1M to $10M)
  18. Amicus Therapeutics ($50M to $100M)
  19. BionPharma ($1M to $10M)
  20. SPES Pharma (Less than $1M)
  21. Drais Pharmaceuticals ($1M to $10M)
  22. Nevakar ($1M to $10M)
  23. Sonnet BioTherapeutics (Less than $1M)
  24. Rafael Pharmaceuticals ($1M to $10M)
  25. Lab Automate Technologies (Less than $1M)
  26. Solaris Pharma (Less than $1M)
  27. Covance ($1B to $10B)
  28. MAIA Pharmaceuticals ($10M to $50M)
  29. Onkos Surgical ($1M to $10M)
  30. Eagle Pharmaceuticals ($10M to $50M)
  31. Amorcyte (Less than $1M)
  32. Amneal Pharmaceuticals ($100M to $500M)
  33. Slayback Pharma ($10M to $50M)
  34. Emisphere Technologies ($1M to $10M)
  35. Apicore ($10M to $50M)
  36. Partners Pharmacy ($100M to $500M)
  37. Teligent ($10M to $50M)
  38. Aerie Pharmaceuticals ($50M to $100M)
  39. Actinobac Biomed ($1M to $10M)
  40. Timber Pharmaceuticals (Less than $1M)
  41. Navinata Health ($1M to $10M)
  42. ImpactRx ($10M to $50M)
  43. Circuport (Less than $1M)
  44. PDS Biotechnology Corporation (Less than $1M)
  45. Vertice Pharma ($10M to $50M)
  46. Macrophage Therapeutics ($1M to $10M)
  47. Origin (Less than $1M)
  48. Genomic Prediction ($10M to $50M)
  49. Catalent Pharma Solutions ($500M to $1B)
  50. Aspargo Laboratories ($10M to $50M)
  51. Celldex Therapeutics (Less than $1M)
  52. Cyclacel Pharmaceuticals (Less than $1M)
  53. B Positive Plasma ($1M to $10M)
  54. Apprentice.io ($10M to $50M)
  55. Herborium Group ($10M to $50M)
  56. Advaxis (Less than $1M)
  57. Paragon Vitamins ($10M to $50M)
  58. Merck ($10M to $50M)
  59. CarePoint Health ($500M to $1B)
  60. Cytosorbents ($1M to $10M)
  61. IVERIC bio ($100M to $500M)
  62. Hepion Pharmaceuticals ($1M to $10M)
  63. MedAvante ($10M to $50M)
  64. Tris Pharma ($100M to $500M)
  65. InnoPharma ($1M to $10M)
  66. Mycell Technologies ($1M to $10M)
  67. Caladrius Biosciences ($10M to $50M)
  68. Celator Pharmaceuticals ($1B to $10B)
  69. JOGO Health (Less than $1M)
  70. WhizAI ($1M to $10M)
  71. TYME Inc ($1M to $10M)
  72. Vyteris ($10M to $50M)


  1. Prolong Pharmaceuticals ($1M to $10M)

    Prolong Pharmaceuticals, Inc. develops and markets biopharmaceutical products. Its products include PEG-uricase for the treatment of hyperuricemia; PEG-arginase for the treatment of melanoma and hepatocellular carcinoma; PEG-protein for the treatment of hypovolemic shock; PEG-peptide antibiotic to treat staphylococcus infections; PEG-streptokinase for myocardial infarcts; anti-cancer agents; and Erythropoietin, a biopharmaceutical that provides a solution for anemia. The company also offers custom manufacturing services; and licenses its products to pharmaceutical companies. Prolong Pharmaceuticals, Inc. was founded in 2002 and is based in New Jersey.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $30M raised in October, 2010
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  2. people sitting on chairs near tables during daytime


  3. Leading Pharma ($1M to $10M)

    Leading Pharma is a privately owned generic pharmaceutical company that purchases, licenses, develops, manufactures and distributes high-quality, safe and effective products to drugstore chains, distributors, wholesalers, mass merchandisers, government agencies and managed care accounts in the U.S. Their products are available in various dosage forms across many therapeutic areas under the Leading label.At Leading, their mission is simple: to provide quality, affordable, safe and effective pharmaceutical products to the people who need them. Their team is dedicated to providing their customers with outstanding customer service, innovative marketing strategies, quality manufacturing, efficient distribution and stringent regulatory compliance to ensure safety every step of the way.

    • $1M to $10M annual revenues
    • 101-250 employees
    • $40M raised in January, 2018
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  4. men sitting of chair inside room


  5. Aquestive Therapeutics ($10M to $50M)

    Aquestive Therapeutics is a specialty pharmaceutical company that advances and commercializes medicines to solve critical healthcare problems and meaningfully improve people’s lives. Aquestive is committed to addressing immediate CNS challenges by furthering its strong pipeline of products. As the undisputed leader in developing and delivering drugs via its proprietary technologies, the Company also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms.

    • $10M to $50M annual revenues
    • 101-250 employees
    • $70M raised in July, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  6. grayscale photo of people in room


  7. Derma Sciences ($50M to $100M)

    Derma Sciences, Inc. is a specialty medical device / pharmaceutical company focused on wound care. As fully integrated manufacturer, marketer and supplier of a complete line of products for wound and skin care, we have full lines of products in the following categories: Advanced Wound Care, Traditional Wound Care, Burn Care, Skin Care and Bathing, Specialty Securement and Closure Devices, and First Aid. With two wholly owned and operated manufacturing facilities in Toronto and China, we also offer exceptional contract manufacturing services for OEM or private label products.

    • $50M to $100M annual revenues
    • 251-500 employees
    • $29.1M raised in July, 2011
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  8. two men using computers


  9. Prokaryotics (Less than $1M)

    Prokaryotics is a biopharmaceutical company focused on the discovery and development of novel antibiotic classes that target serious multi-drug resistant bacterial infections. Prokaryotics leverages deep knowledge of bacterial physiology, innovative screening strategies, and scientific excellence necessary to discover and develop new classes of antibiotics targeting outer membrane biogenesis - the fundamental armor erected by bacteria to naturally withstand the effects of antibiotics.

    • Less than $1M annual revenues
    • 1-10 employees
    • $2.5M raised in March, 2018
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  10. two women sitting beside table using MacBooks


  11. DiRx Health (Less than $1M)

    DiRx is a digital pharmacy that offers safe, affordable, in-home delivery of generic medications to US consumers with no insurance needed.

    • Less than $1M annual revenues
    • 11-50 employees
    • $5M raised in September, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  12. people sitting beside rectangular brown table with laptops


  13. RespireRx Phamaceuticals (Less than $1M)

    RespireRx Pharmaceuticals Inc. is focused on developing drug candidates to treat very large respiration related markets that are unserved or poorly served. RespireRx is also developing drugs for niche respiratory markets where premium pricing is probable. All of the Company’s current efforts are involved with sleep apnea/hypopnea, respiratory depression and respiratory distress.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.2M raised in November, 2014
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  14. selective focus photography of desk lamp on table


  15. TAXIS Pharmaceuticals (Less than $1M)

    TAXIS Pharmaceuticals is a privately held biopharmaceutical company dedicated to developing compounds to target the growing threat of antimicrobial resistance, including antibacterial and antiviral resistance. We are currently focused on antibiotic agents that employ novel mechanisms of action distinct from those currently in clinical use. Our team’s expertise in discovery chemistry, combined with our spirit of innovation, allows us to quickly pinpoint promising compounds that exhibit the key properties required for a clinical drug candidate.

    • Less than $1M annual revenues
    • 1-10 employees
    • $3M raised in June, 2016
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  16. rectangular brown wooden table


  17. BodyBio ($10M to $50M)

    BodyBio is a nutritional supplement company that is relentlessly focused on the pursuit of health at the cellular level. Its founders are leading researchers in the field of complex metabolic disorders, fatty acid analysis, and the idea that cellular health is at the core of all health. With more than two decades of published scientific research, BodyBio has developed a series of transformative products, most notably, BodyBio’s liposomal Phosphatidylcholine. BodyBio’s range of products support cellular health and are utilized globally as alternative treatment methods for neurological and psychological disorders. BodyBio is committed to continuing to push the boundaries of what’s possible in human vitality and performance through the highest standards of quality, efficacy, curiosity and research.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $0.7M raised in May, 2018
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  18. people having meeting on rectangular brown table


  19. Elite Pharmaceuticals ($1M to $10M)

    Elite Pharmaceuticals, Inc. specializes in the development of oral controlled release products, such as delayed, sustained, targeted and pulsatile release tablets, pellets, capsules, granules and powders. The Company’s primary focus is in the therapeutic areas of pain management, allergy, cardiovascular and infection.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $0.5M raised in July, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  20. three women sitting around table using laptops


  21. Outlook Therapeutics ($1M to $10M)

    Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics. It is advancing its pipeline of 11 biosimilar products, two of which are currently in clinical development. The company employs its BioSymphony biosimilars business model to achieve accelerated development and technical excellence in order to create affordable medicines for patients around the world.

    • $1M to $10M annual revenues
    • 101-250 employees
    • $35M raised in January, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  22. photo of industrial machines near table


  23. Protalex (Less than $1M)

    Protalex is a development stage company that develops a class of biopharmaceutical drugs designed to treat autoimmune and inflammatory, including rheumatoid arthritis. PRTX-100 The company’s lead product, PRTX-100, is a formulation of a proprietary, highly-purified form of the Staphylococcal bacterial protein known as Protein A, which is an immune-modulating protein produced by bacteria. PRTX-100 has the ability, at very low concentrations, to bind to and to regulate activation of human B-lymphocytes and macrophages which mediate inflammation in certain autoimmune diseases. PRTX-100 is in Phase 1b clinical trial for the treatment of patients with rheumatoid arthritis. Patents, Trademarks, and Proprietary Technology The company filed an initial therapeutic use patent application with the U.S. Patent and Trademark Office, which issued in May 2007, as U.S. 7,211,258 (the 258 Patent). The 258 Patent has claims relating to the treatment of acute inflammation, as well as rheumatoid arthritis and systemic lupus erythematosus using protein A. A second patent claiming the use of protein A to treat idiopathic thrombocytopenia or autoimmune thrombocytic purpura issued as U.S. 7,425,331. A further patent for the use of protein A issued as U.S. 7,807,170 in 2010 (the 170 Patent). The 170 Patent claims the use of protein A to reduce an acute inflammatory response or inflammation, including when these symptoms are associated with myasthenia gravis, ulcerative colitis, Crohn’s disease, psoriatic arthritis, or pemphigus Vulgaris. A further patent claiming the use of protein A to treat psoriasis and scleroderma issued as U.S. 8,168,189 in 2012. The company has also filed for foreign patent protection in Canada, Japan, and the European Union. Japanese patent JP 4598404 issued in 2010 with claims relating to the use of protein A to treat rheumatoid arthritis, systemic lupus erythematosus, idiopathic thrombocytopenia, and autoimmune thrombocytopenic purpura. It was founded in 1999 and is based in Florham Park, New Jersey.

    • Less than $1M annual revenues
    • 1-10 employees
    • $2.8M raised in January, 2014
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  24. group of people sitting beside rectangular wooden table with laptops


  25. Amerigen Pharmaceuticals ($1M to $10M)

    company that was founded in 2007 by a group of healthcare investors. The company has a focus on the development, manufacture and sale of high quality generic pharmaceutical products for two of the most important markets in the world…the United States and China. Our US office is located in central New Jersey. In addition to executive management, this location also houses staff in the following functions for the US market: product and business development, finance, regulatory affairs, and commercial operations. Product development is being undertaken at various locations around the world under the supervision of its experienced R&D, quality, and regulatory leaders.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $35M raised in January, 2015
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  26. rectangular brown wooden table with chair lot inside building


  27. Vascular Therapies ($1M to $10M)

    Vascular Therapies (VT) is a biopharmaceutical company committed to the development and commercialization of innovative new treatments to address major unmet clinical needs of patients requiring a vascular access to support hemodialysis. Our lead product candidate, containing sirolimus, has received orphan drug designations in the U.S. and E.U. for the dialysis vascular access indications. The company was founded in 2001 and headquartered in Cresskill, New Jersey.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $17.3M raised in January, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  28. people sitting and using laptops


  29. Provention Bio ($500M to $1B)

    Provention Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease. Their “predict and prevent” model is focused on developing novel therapeutic approaches that intervene before the target disease begins, re-appears or progresses. As such, we believe Provention is well-positioned to become a leader in a new biopharmaceutical category centered on the interception of disease, offering the potential to reduce the high-morbidity, mortality, patient suffering and escalating costs of chronic autoimmune and inflammatory diseases, such as type 1 diabetes (T1D), Crohn’s disease, ulcerative colitis, and emerging viral infections. Provention has been carefully conceived, founded and positioned to be at the forefront of this pioneering new paradigm in medicine. They believe Provention’s business model, coupled with our expertise in translational medicine, immunology and the design and execution of rapid go/no-go clinical trials, will enable us to in-license and efficiently partner both early-stage development assets and more advanced clinical-stage opportunities.

    • $500M to $1B annual revenues
    • 11-50 employees
    • $100M raised in January, 2021
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  30. KBP Biosciences ($1M to $10M)

    KBP is a world-class biotechnology research & development organization dedicated to providing innovative therapies for unmet medical needs.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $76M raised in January, 2018
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  31. people sitting in front of computer monitors


  32. Welmedix Consumer Healthcare ($1M to $10M)

    Welmedix Consumer Healthcare develops and markets pharmaceutical products. The company was founded in 2005 and is headquartered in Princeton, New Jersey.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $6.3M raised in December, 2015
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  33. brown wooden table and chairs


  34. Amicus Therapeutics ($50M to $100M)

    Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases. The Company has a robust pipeline of novel, first-in-class, small molecules called pharmacological chaperones for the treatment of lysosomal storage diseases (LSDs). These chaperones may offer a dual-treatment approach for Fabry, Pompe, Gaucher and other LSDs. As orally administered monotherapy agents, pharmacological chaperones are designed to bind to, stabilize and increase the activity of a patient’s own misfolded enzyme. In combination with enzyme replacement therapy (ERT), pharmacological chaperones may improve the uptake of the infused enzyme and potentially improve ERT outcomes.

    • $50M to $100M annual revenues
    • 51-100 employees
    • $10M raised in December, 2013
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  35. architectural photo of buildings during daytime


  36. BionPharma ($1M to $10M)

    BionPharma develops and commercializes affordable quality generics and builds strong and effective partnerships. It is licensed to do business in the United States and is accomplished in the areas of product development, regulatory affairs, quality management, sales and distribution, and supply chain management. Today, Bionpharma is one of the largest suppliers of soft gel capsules in the US market with a strong presence in both the prescription and over-the-counter markets. Launched in 2014, BionPharma was founded by a team of executives and professionals with years of cumulative experience in the generics industry. It is based in Princeton, New Jersey, and with offices in Raleigh, North Carolina.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $6.5M raised in December, 2015
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  37. men using computers


  38. SPES Pharma (Less than $1M)

    SPES is a specialty pharmaceutical company focusing on patient medical needs through innovative science and technologies. The company is developing twelve 505(b)(2) products based on three innovative platforms. The candidate products are targeting therapeutic areas including oncology, antiemetic, CNS, and pain management to provide patients with safer and more efficient treatment options.

    • Less than $1M annual revenues
    • 1-10 employees
    • $2M raised in June, 2017
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  39. man in black jacket sitting on chair


  40. Drais Pharmaceuticals ($1M to $10M)

    Drais Pharmaceuticals, Inc. is a venture capital supported drug development company with an exciting new business model. Through strong relationships with Astellas Pharma Inc. and our venture capital investors - InterWest Partners, Sutter Hill Ventures, and Astellas Venture Management LLC, we have created multiple virtual companies to enable the development of interesting novel compounds in a variety of therapeutic areas. Our focus is on early stage development through proof of concept. Our business model relies on a small internal team who provide drug development services to those virtual companies via vendors and CROs. Our internal experts are able to move compounds rapidly through key development milestones and decision points, thus de-risking programs early in development.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $13M raised in June, 2012
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  41. brown and white table and chairs


  42. Nevakar ($1M to $10M)

    Nevakar is a specialty pharmaceutical company, focused on developing innovative products in injectable and ophthalmic space.Their goal is to develop enhanced products that address unmet clinical and/or commercial needs of currently [FDA] approved molecules, through intensive R&D and clinical efforts.Nevakar’s business model is supported by state of the art R&D infrastructure, located in NJ Center of Excellence, and a well experienced management and leadership team.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $30M raised in November, 2018
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  43. people sitting on black chairs


  44. Sonnet BioTherapeutics (Less than $1M)

    Sonnet BioTherapeutics is a biotechnology company for innovating biologic drugs of the single or bispecific mechanism of action. The company 's proprietary FHAB™ (Fully Human Albumin Binding) technology enables the development of innovative targeted biologic drugs with enhanced single- or bi-specific mechanisms. The FHAB™ platform utilizes a fully human single-chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. Sonnet’s FHAB construct attaches to albumin in the bloodstream, which significantly enhances the pharmacokinetics of the active drug substance. It also naturally accumulates at inflammation sites, including tumors, thereby potentiating delivery to target tissues. The Sonnet platform is differentiated in that FHAB utilizes a fully human sequence, with a human glycosylation profile that can be manufactured using a standard CHO process. Sonnet BioTherapeutics was founded in 2011 and is headquartered in Princeton, New Jersey, USA.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.8M raised in April, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  45. people using desktop computer inside office


  46. Rafael Pharmaceuticals ($1M to $10M)

    Rafael Pharmaceuticals is a provider of metabolic oncology therapeutics intended to treat cancer patients. The company's metabolic oncology therapeutics applies unique bio-energetic processes specific to cancer and provide altered cancer metabolism directed therapies and novel, first-in-class drugs and drug delivery technologies, enabling patients to get revolutionized cancer treatment.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $10M raised in November, 2016
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  47. rolling armchair beside table


  48. Lab Automate Technologies (Less than $1M)

    Lab Automate Technologies meets the Automation requirements of the Bio-Tech, Pharmaceutical, Food, Chemical and the Environment Control Industry by designing and developing cost effective automation solutions to help our clients stay ahead of competition in the Global Markets.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.1M raised in October, 2012
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  49. Solaris Pharma (Less than $1M)

    Solaris Pharma is a fully equipped Research & Development facility with expertise in the development of generic and specialty products. They have the vision of improving the patients’ quality of life through the development of niche pharmaceutical products. Solaris Pharma Corporation has a fully equipped Research & Development facility with expertise in the development of generic and specialty products. Solaris Pharma Corporation is uniquely poised to develop specialty dermatology products that have a relatively high barrier to entry due to manufacturing complexities and high-end clinical patient study demands. Solaris Pharma Corporation was founded in 2014 and is located in Bridgewater, New Jersey.

    • Less than $1M annual revenues
    • 11-50 employees
    • $10M raised in December, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  50. man in gray sweatshirt sitting on chair in front of iMac


  51. Covance ($1B to $10B)

    Covance Inc. provides early-and late-stage services to the pharmaceutical, biotechnology, and medical device industries. Its early-stage development services include preclinical and clinical pharmacology services. The company's late-stage services include biomarker services to biotech and pharmaceutical customers, with full management of Phase II and III clinical studies. It also provides lab testing services to the chemical, agrochemical, and food industries. The company was founded in 1987 and is based in Princeton, N.J. Covance, the drug development business of Laboratory Corporation of America Holdings (LabCorp), is the world’s most comprehensive drug development company, dedicated to advancing healthcare and delivering Solutions Made Real® by providing high-quality nonclinical, clinical and commercialization services to pharmaceutical and biotechnology companies to help reduce the time and costs associated with drug development. Because of their broad experience and specialized expertise, they are in a unique position to supply insights that go above and beyond testing -- They have helped pharmaceutical and biotech companies develop each of the top 50 prescription drugs in the marketplace today. They also offer laboratory testing services to the chemical, agrochemical and food industries and are a market leader in toxicology services, central laboratory services, discovery services, and a top global provider of Phase III clinical trial management services.

    • $1B to $10B annual revenues
    • 10001+ employees
    • $1.3M raised in April, 2015
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  52. people standiunmg


  53. MAIA Pharmaceuticals ($10M to $50M)

    MAIA Pharmaceuticals company that identifies, develops, manufactures, and markets innovative and niche generic products. It specializes in the fields of providing injectables, niche generic, diagnostics, hormones, and oncology. It was founded in 2013 and headquartered in Princeton, New Jersey.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $0.8M raised in October, 2014
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  54. tennis table in room


  55. Onkos Surgical ($1M to $10M)

    There are huge opportunities for innovation where the complexity of the disease state requires more diverse solutions. Onkos Surgical will be 100% focused on bringing new technology and solutions to surgical oncologists who serve a population of which a large portion of the patients are children and the broader population may require personalized solutions.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $7.6M raised in April, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  56. man and woman sitting at table


  57. Eagle Pharmaceuticals ($10M to $50M)

    Eagle Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing injectable products, primarily in the critical care and oncology areas, using the 505(b)(2) regulatory pathway.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $12.3M raised in February, 2011
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  58. grey wooden table and black leather rolling chairs


  59. Amorcyte (Less than $1M)

    Amorcyte is a privately held biotechnology company developing cell therapy products to treat cardiovascular disease. Its lead product AMR–001, for the prevention of major adverse cardiac events following acute myocardial infarction (AMI), has completed Phase I clinical trials demonstrating feasibility, safety and biologic activity at a threshold dose. This is the first stem cell trial in AMI ever conducted that has prospectively established a significant relationship between dose and effect. Amorcyte has partnered with Progenitor Cell Therapy, a leading provider of clinical, manufacturing and other services for the cell therapy industry, to provide Amorcyte with a pharmaceutical grade cGMP manufactured product that can be distributed commercially. Amorcyte was founded by Andrew Pecora, M.D., Chairman of The John Theurer Cancer Center at Hackensack University Cancer Center, with initial investment by Novitas Capital and Colt Ventures.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.5M raised in July, 2011
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  60. people sitting on chairs near tables during daytime


  61. Amneal Pharmaceuticals ($100M to $500M)

    Amneal is much more than just a company. It is a remarkable collection of dynamic and innovative people dedicated to the constant pursuit of excellence.

    • $100M to $500M annual revenues
    • 5001-10000 employees
    • $854M raised in October, 2017
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  62. men sitting of chair inside room


  63. Slayback Pharma ($10M to $50M)

    Slayback is founded on the principle of “connecting the dots”. This principle translates into their philosophy of connecting one idea with another. The idea is to conceptualize and develop complex generic and specialty drugs. They focus on products that are challenging and highly complex to develop and/or manufacture. It could be a complex oil-in-water emulsion or a sterile long acting injectable using nano-spheres or sterile suspensions with complex particle physics. They have also worked on complex hormonal products with challenging cross-contamination issues. They aim to optimize the use of technology and potential (generated from a strong experience in this field) to develop a value proposition for their customers. Through this process of drug development, they remotely aim at reducing the cost of therapy by bringing expensive branded drugs within the reach of patients.

    • $10M to $50M annual revenues
    • 101-250 employees
    • $50M raised in January, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  64. grayscale photo of people in room


  65. Emisphere Technologies ($1M to $10M)

    Emisphere is a pharmaceutical company utilizing its proprietary Eligen Technology to create new oral formulations of therapeutic agents. Emisphere currently has a number of product candidates in its pipeline at varying stages. There are multiple product candidates in clinical development as well as several pre-clinical development/research programs. The Company considers specific criteria when deciding whether to devote resources to a development program. The markets that Emisphere seeks to enter for a potential product should be substantial. The product candidate should meet a clear unmet medical or market need and the product profile should clearly differentiate Emisphere's products. The Company also considers the level of product development effort in relation to a reasonable return on investment within an acceptable timeframe.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $20M raised in August, 2014
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  66. two men using computers


  67. Apicore ($10M to $50M)

    Apicore provides process R&D and API manufacturing services for the pharmaceutical industry worldwide. The company's specialty active pharmaceutical ingredients specialize in the manufacture of difficult to synthesize, high value, and other niches API's, enabling a wide range of customers in the generic medicine industry to avail products at market competitive costs used for custom synthesis for early phase pharmaceutical research and branded products.

    • $10M to $50M annual revenues
    • 101-250 employees
    • $0.7M raised in October, 2016
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  68. two women sitting beside table using MacBooks


  69. Partners Pharmacy ($100M to $500M)

    Partners Pharmacy is proud to be one of the top three largest long-term care pharmacy companies in the U.S. today. As one of the nation’s premier providers, Partners Pharmacy offers the full range of resources required to effectively serve the comprehensive medication needs of skilled nursing facilities, long-term care residences, assisted living communities and their residents. Partners is a solution-focused enterprise employing 800 people, offering innovative technologies, advanced clinical systems and multiple pharmacy locations – all poised to provide the highest quality pharmacy care available to facility residents.

    • $100M to $500M annual revenues
    • 501-1000 employees
    • $60M raised in August, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  70. people sitting beside rectangular brown table with laptops


  71. Teligent ($10M to $50M)

    Teligent develop, manufacture and market pharmaceutical products for use by doctors and patients in the United States and Canada. They are a dynamic group of about 130 employees based in New Jersey, Toronto, Montreal and Tallinn, Estonia. Their Product Development and Manufacturing complex is in Buena, New Jersey, approximately 45 minutes from Philadelphia. In 2015 They acquired Alveda Pharmaceuticals Inc., a Toronto-based pharmaceutical company focused on the Canadian injectable pharmaceutical market. In 2016 They hired Their first European colleagues in Tallinn who support Their supply chain and quality operations.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $2M raised in January, 2013
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  72. selective focus photography of desk lamp on table


  73. Aerie Pharmaceuticals ($50M to $100M)

    Aerie Pharmaceuticals, Inc., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of ophthalmic diseases. It focuses on the development of products for the pharmaceutical treatment of glaucoma. The company was founded in 2005 and is headquartered in Bridgewater, New Jersey with research facilities in Research Triangle Park, North Carolina. Aerie Pharmaceuticals, Inc. is a former subsidiary of Duke University Medical Center.

    • $50M to $100M annual revenues
    • 251-500 employees
    • $316.5M raised in September, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  74. rectangular brown wooden table


  75. Actinobac Biomed ($1M to $10M)

    Actinobac Biomed focuses on the development of pharmaceutical technologies derived from agents that target Leukocyte Function Antigen-1 (LFA-1). The company's lead product, Leukotoxin, is a bacterial toxin that specifically targets white blood cells. In addition to its use as an effective targeted therapy agent for the treatment of hematologic malignancies, abundant evidence in literature suggests that Leukotoxin, or a derived product, can effectively be used to treat infectious diseases such as HIV/AIDS and tuberculosis, as well as many autoimmune diseases including rheumatoid arthritis, multiple sclerosis, Crohn’s disease, type 1 diabetes, Lupus and psoriasis. Therefore, the company will direct its efforts in three strategic areas. The first, and highest priority, is the development of Leukotoxin as a protein therapeutic for the treatment of hematologic malignancies. The second will focus on the use of Leukotoxin and derived therapeutic peptides or mimetics for the treatment of significant diseases other than hematologic malignancies, including infections and autoimmune diseases. The third area represents an early-stage drug discovery program with Magellan BioScience that will maintain a healthy pipeline of novel therapeutic agents.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $1M raised in June, 2018
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  76. people having meeting on rectangular brown table


  77. Timber Pharmaceuticals (Less than $1M)

    Timber Pharmaceuticals is a privately held biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.5M raised in April, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  78. three women sitting around table using laptops




  79. ImpactRx ($10M to $50M)

    ImpactRx, Inc. operates as a promotion research organization for the pharmaceutical industry in the United States. The company tracks and evaluates the impact of pharmaceutical promotions on the prescribing behavior of the physicians. Its ImpactRx technology enables to collect and process the information on the perceptions and activities of physicians, as well as allows pharmaceutical companies to diagnose and predict the efficiency and effectiveness of sales and marketing initiatives. The company structures its data into a range of syndicated and semi-custom products in the areas of brand management and market research, sales management, managed care marketing, and oncology sales and marketing to assist pharmaceutical and biotech enterprises in decision making. ImpactRx, Inc. was founded in 2000 and is headquartered in Mount Laurel, New Jersey.

    • $10M to $50M annual revenues
    • 51-100 employees
    • $1.2M raised in January, 2010
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  80. group of people sitting beside rectangular wooden table with laptops


  81. Circuport (Less than $1M)

    Circuport, Inc. provides vascular access systems for hemodialysis patients. It offers Circuport System that features an implantable port for access to the patient's vessel and a frame that prevents the compression of blood vessels during access with the dialysis needle. The company was incorporated in 2006 and is based in Morristown, New Jersey.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.8M raised in June, 2010
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  82. rectangular brown wooden table with chair lot inside building


  83. PDS Biotechnology Corporation (Less than $1M)

    PDS Biotechnology Corporation is a biopharmaceutical company. It develops immunotherapies for cancer and other infectious diseases. It develops products to prevent and treat cervical, ovarian, melanoma, leukemia, pancreatic, oral, multiple myeloma, anal, vulvar, and penile cancers. The company offers PDS0101, a treatment for HPV-related cancers; PDS0102, a pandemic influenza vaccine; and PDS0103, a line of immunotherapy products for non-viral cancers. PDS Biotechnology Corporation was founded in 2005 and is headquartered in North Brunswick, New Jersey.

    • Less than $1M annual revenues
    • 1-10 employees
    • $1.1M raised in September, 2016
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  84. people sitting and using laptops


  85. Vertice Pharma ($10M to $50M)

    Vertice Pharma is a specialty pharmaceuticals company focused on improving patients’ health. Vertice Pharma develops, manufactures, markets, and distributes high-quality and affordable pharmaceutical products through its operating companies. Vertice Pharma has global headquarters in the United Kingdom and United States headquarters in New Jersey.

    • $10M to $50M annual revenues
    • 101-250 employees
    • $300M raised in November, 2015
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  86. Macrophage Therapeutics ($1M to $10M)

    Macrophage Therapeutics (MT) is developing novel immuno-oncology and targeted anti-inflammatory therapeutics based on its proprietary Activated Macrophage targeting platform. MT is leveraging its unique CD206 receptor-based delivery system to deliver proven therapeutics in a more precise and targeted fashion. With binding affinities 10,000X today’s best antibodies MT’s approach eliminates off-target toxicity and increases the efficacy of proven therapeutic agents. MT’s CD206 targeting platform is already clinically established and being used in an FDA/EMEA approved radiopharmaceutical.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $2.5M raised in March, 2015
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  87. people sitting in front of computer monitors


  88. Origin (Less than $1M)

    Origin is a privately held, clinical-stage biotechnology company founded in June 2010 to develop and commercialize our novel, patented medical technology — delivering plasma-stream therapeutic molecules generated right at the point of care. Their technology is based on Nobel prize-winning research and is designed to surpass current standards of care in efficacy, side effects, and/or cost-effectiveness. Origin (formerly Advanced Plasma Therapies) was founded in 2010 to become an active participant in the plasma-medicine arena. Plasma medicine is an innovative and emerging field combining plasma physics, life sciences and clinical medicine to use physical plasma for therapeutic applications. It is the subject of advanced study at major academic institutions in the United States, Russia, Germany, Japan, the United Kingdom, France and Italy.

    • Less than $1M annual revenues
    • 1-10 employees
    • $1.3M raised in May, 2017
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  89. brown wooden table and chairs


  90. Genomic Prediction ($10M to $50M)

    Genomic Prediction provides advanced genetic testing for IVF. They have developed a novel, genome-wide molecular genotyping methodology for pre-implantation genetic testing of embryos.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $4.5M raised in January, 2019
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  91. architectural photo of buildings during daytime


  92. Catalent Pharma Solutions ($500M to $1B)

    Catalent Pharma Solutions, Inc. provides drug delivery technologies and outsourced development, manufacturing, and packaging services to the pharmaceutical, biotechnology, and consumer health industry worldwide. It operates in four segments: Development and Clinical Services, Oral Technologies, Sterile Technologies, and Packaging Services. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management for drugs and biologics in clinical trials. It also offers analytical chemical and cell-based testing and scientific services, respiratory products formulation and manufacturing, regulatory consulting, and biologics proprietary expression technology, and product development. The Oral Technologies segment provides formulation, development, and manufacturing services for the oral dose forms. Its oral drug delivery technologies include proprietary delivery technologies for drugs and consumer health products. This segment also offers formulation, development, and manufacturing services for conventional oral dose forms, including controlled release formulations, as well as immediate release tablets and capsules. The Sterile Technologies segment provides proprietary and traditional dose forms for separate routes of administration. It offers formulation and development for injectable drugs; and fills drugs or biologics into vials, pre-filled syringes, bags, and other sterile delivery formats. This segment's blow-fill-seal technology provides integrated dose form creation and filling of sterile liquids in a single process for respiratory, ophthalmic, and other routes of administration. The Packaging Services segment offers packaging services for pharmaceuticals, biologics, consumer health, and veterinary products, which include packaging drugs in blisters, bottles, pouches, and unit doses; and printed components, such as creating package inserts or folding cartons. The company is based in Somerset, New Jersey.

    • $500M to $1B annual revenues
    • 5001-10000 employees
    • $550M raised in February, 2021
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  93. men using computers


  94. Aspargo Laboratories ($10M to $50M)

    Aspargo Laboratories commercialize the rights of an oral suspension spray formulation of erectile dysfunction medication Sildenafil citrate. Spray formulation offers convenient drug administration, flexible-dose titration, and accessibility for patients with dysphagia (trouble swallowing). The company is developing patient-focused solutions and medicines by combining our innovative science and technology. Its initial product candidate is a proprietary oral suspension spray formulation of sildenafil citrate, the active ingredient in VIAGRA Currently, it has approved for sale in 9 European countries and 8 Latin American countries, with pending approvals in Portugal, Mexico, Italy, Czech Republic, Slovak Republic, Greece, Australia, and China. Applications for approval are planned for Croatia, France, Germany, and Austria.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $7.9M raised in February, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  95. man in black jacket sitting on chair


  96. Celldex Therapeutics (Less than $1M)

    Celldex Therapeutics (NASDAQ: CLDX) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. The Company’s pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers—including many underserved or completely un-served orphan indications. This has created a leading pipeline in immunotherapy comprised of two candidates in pivotal trials, one in brain cancer and one in triple negative breast cancer, four additional clinical candidates in a range of difficult-to-treat indications and a robust preclinical engine.

    • Less than $1M annual revenues
    • 101-250 employees
    • $2M raised in October, 2014
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  97. brown and white table and chairs


  98. Cyclacel Pharmaceuticals (Less than $1M)

    Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Professor Sir David Lane, a recognized leader in the field of tumor suppressor biology, who discovered the p53 protein, founded the Company in 1996. In 1999, Cyclacel Pharmaceuticals was joined by Professor David Glover, a recognized leader in the mechanism of mitosis or cell division, who discovered, among other cell cycle targets, the mitotic kinases, Polo and Aurora, enzymes that act in the mitosis phase of the cell cycle.

    • Less than $1M annual revenues
    • 11-50 employees
    • $15.2M raised in July, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  99. people sitting on black chairs


  100. B Positive Plasma ($1M to $10M)

    B Positive Plasma collects blood plasma to be used in the creation of life-saving therapies. The company allows people to donate their plasma, while also getting financially compensated for their time. The compensation donors receive is recycled back into the community as donations to charities or faith-based organizations, through the support of neighboring retail and entertainment establishments, and as funding for family activities.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $0.2M raised in June, 2014
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  101. people using desktop computer inside office


  102. Apprentice.io ($10M to $50M)

    Apprentice.io develops an intelligent manufacturing execution system that helps life science teams scale faster. From small and large molecule to cell and gene therapy, Apprentice's cloud-based system leverages artificial intelligence, augmented reality, and Pharma 4.0 to increase an organization's speed to market. Run your entire batch campaign and leverage data for continuous process improvement. It was formed in 2014 and headquartered in New Jersey, United States.

    • $10M to $50M annual revenues
    • 101-250 employees
    • $24M raised in November, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  103. rolling armchair beside table


  104. Herborium Group ($10M to $50M)

    Herborium Group, Inc., a botanical therapeutics company, provides natural and complementary healthcare related products to consumers and healthcare professionals. The company engages in the development, license, and marketing of botanical based medicinal products. It offers dermatology products, which include AcnEase, a herbal medicine product for natural acne and rosacea treatment; and AcnEase Skin Management System for the treatment of acne marks/scars. The company also provides sexual health and performance products that are non-prescriptive alternatives to selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, and even surgical procedures, including hysterectomy. In addition, it offers energy restoration products, such as Lasting Energy, a herbal supplement to combat stress, depletion of energy, jet-lag, and hangover; and for treating overall depletion of energy due to competitive sports, high levels of stress, and extensive sexual activities, as well as other long term or temporary physical demands. Further, the company provides Liver Activator Series for the treatment of liver damage; ProstAid, an all natural product focused on Benign Prostate Hyperplasia; and CardioVitae, a fermentation based product using a Lucidium derived cell line targeting cardio-pulmonary insufficiencies. Herborium Group, Inc. sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce. The company was founded in 2000 and is based in Teaneck, New Jersey.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $0.1M raised in November, 2011
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  105. Advaxis (Less than $1M)

    Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself. ADXS-HPV is being evaluated in four clinical trials for HPV-associated diseases: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (GOG/NCI US study), head and neck cancer (CRUK study), and anal cancer (BrUOG). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence.

    • Less than $1M annual revenues
    • 51-100 employees
    • $30M raised in August, 2016
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  106. man in gray sweatshirt sitting on chair in front of iMac


  107. Paragon Vitamins ($10M to $50M)

    Paragon Vitamins is a vitamin company that generates a custom wellness solution based on unique bio-blueprint. Paragon Vitamins analyzes and assesses individuals' health (using a Hair Tissue Mineral Analysis and a proprietary questionnaire) and design comprehensive personalized wellness regimens inclusive of nutrition, exercise, and vitamin supplements, allowing customers to balance their biochemistry and enhance wellness and performance with greater control, personalization, and convenience.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $1.5M raised in June, 2019
    • 5 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  108. people standiunmg


  109. Merck ($10M to $50M)

    Merck is a biopharmaceutical company that offers medicines and vaccines for various diseases. The company is driven by a mission to discover, develop, and provide innovative products and services that save and improve lives around the world. Merck delivers vaccines, medications, and consumer and animal health products that can help millions around the world. Merck was founded in 1891 and is headquartered in Kenilworth, NJ.

    • $10M to $50M annual revenues
    • 10001+ employees
    • $0.6M raised in November, 2018
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  110. tennis table in room


  111. CarePoint Health ($500M to $1B)

    CarePoint Health, Inc. operates mainly in Texas, USA providing end-to-end non-institutional healthcare services to clients. Licensed by The Texas Department of Health and accredited by The Joint Commission (JCAHO), CarePoint Health has a committed focus on quality management programs by constantly monitoring, evaluating, and improving agency operations. CarePoint Health, Inc. operates out of 3 regional offices in Texas.

    • $500M to $1B annual revenues
    • 5001-10000 employees
    • $0.4M raised in August, 2014
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  112. man and woman sitting at table


  113. Cytosorbents ($1M to $10M)

    CytoSorbents Corporation is a publicly-traded, critical care focused therapeutic device company using blood purification to treat life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Each polymer bead contains millions of pores and channels that can be modified to remove substances as small as drugs, to substances as large as antibodies.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $5M raised in August, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  114. grey wooden table and black leather rolling chairs


  115. IVERIC bio ($100M to $500M)

    Ophthotech Corporation, a biopharmaceutical company, develops various therapeutics to treat diseases of the eye. It is developing Fovista, which has completed Phase IIb clinical trials for use in combination with anti-VEGF drugs for the treatment of wet age-related macular degeneration (wet AMD); and ARC1905, a potent and selective inhibitor of complement factor C5 that has completed Phase I/IIa clinical trials to treat wet AMD. The company was founded in 2007 and is headquartered in New York, New York.

    • $100M to $500M annual revenues
    • 51-100 employees
    • $41.7M raised in January, 2014
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  116. people sitting on chairs near tables during daytime


  117. Hepion Pharmaceuticals ($1M to $10M)

    Hepion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection (HBV, HCV, HDV). Its drug candidate, CRV431, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. Its former name is ContraVir Pharmaceuticals. It was founded in 2013 and is based in Edison, New Jersey.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $9M raised in October, 2014
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  118. men sitting of chair inside room


  119. MedAvante ($10M to $50M)

    Since 2005, MedAvante has provided trial sponsors with a highly trained and standardized cohort of expert Central raters to remotely perform live interviews with subjects at investigative sites via videoconferencing or telephone – and delivered conclusive outcomes in dozens of global trials.

    • $10M to $50M annual revenues
    • 101-250 employees
    • $2M raised in July, 2015
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  120. grayscale photo of people in room


  121. Tris Pharma ($100M to $500M)

    Tris Pharma, Inc. is focuses on the development of pharmaceutical science and technology-based products. Specifically, we are engaged in research, development, manufacturing, and commercialization of both branded products and specialty generic products. We have more than a dozen solid and liquid products in the U.S. market based on our numerous NDAs and ANDAs and a rich and growing portfolio of more than 30 U.S. granted patents. Our commercialization success is driven by internal resources for our pediatric products and by licensing of our non-pediatric products to other companies.

    • $100M to $500M annual revenues
    • 501-1000 employees
    • $125M raised in October, 2018
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  122. two men using computers


  123. InnoPharma ($1M to $10M)

    InnoPharma, LLC. Founded in 2005, is a privately held pharmaceutical research and development (R&D) company, based in Piscataway, New Jersey.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $20M raised in November, 2013
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  124. two women sitting beside table using MacBooks


  125. Mycell Technologies ($1M to $10M)

    Mycell Technologies is an ingredients and technology company that develops proprietary liquid formulation of stable, highly concentrated Omega-3s for use in food, beverage, medical and nutritional products. They offer a range of superior and stable Omega-3 emulsions that are water-soluble and crystal clear in the finished product and have no impact on taste, odor, appearance, or texture. Mycell Technologies was founded in 2009 and headquartered in Paramus, New Jersey.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $1.2M raised in May, 2016
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  126. people sitting beside rectangular brown table with laptops


  127. Caladrius Biosciences ($10M to $50M)

    Caladrius Biosciences is a clinical-stage biopharmaceutical company pioneering advancements of cell therapies for select cardiovascular and autoimmune diseases. The company's current product candidates include three developmental treatments for cardiovascular diseases based on CD34+ cell therapy platform: CLBS12, recipient of a SAKIGAKE designation in Japan and advanced therapy medicinal product classification (ATMP) in Europe, eligible for early conditional approval for the treatment of critical limb ischemia in Japan based on an ongoing clinical trial; CLBS16, subject of the proof-of-concept ESCaPE-CMD clinical trial in the U.S.A. and CLBS14, a Phase 3 clinical program in no option refractory disabling angina and recipient of a RMAT designation in the U.S.A.

    • $10M to $50M annual revenues
    • 101-250 employees
    • $65M raised in February, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  128. selective focus photography of desk lamp on table


  129. Celator Pharmaceuticals ($1B to $10B)

    Celator Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies to treat cancer. The company focuses on CombiPlex, a drug ratio technology platform that enables to the development of combination therapies. Its products include CPX-1 (Irinotecan HCI-Floxuridine), a treatment for colorectal cancer; and CPX-351 (Cytarabine-Daunorubicin), a treatment for acute myeloid leukemia (AML). Celator Pharmaceuticals, Inc. was formerly known as Celator Technologies, Inc. The company was founded in 2000 and is headquartered in Princeton, New Jersey.

    • $1B to $10B annual revenues
    • 11-50 employees
    • $39.3M raised in April, 2013
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  130. rectangular brown wooden table


  131. JOGO Health (Less than $1M)

    JOGO is a Digital Therapeutics (DTx) uses the clinically proven science of neuroplasticity and biofeedback to treat patients with neuromuscular conditions and chronic pain. JOGO is composed of wearable sensors, and a patent protected Mobile App that leverages AI/ML and VR to provide treatment protocols and games that can be adapted for muscle relaxation, movement coordination, and neuro-muscular re-education. JOGO therapy is provided as JaaS (JOGO as a Service) at a doctor's office, home visit or via Telemedicine by certified JOGO therapists. JOGO received FDA 510K exemption in March 2020 during COVID-19 pandemic and JaaS is reimbursed by Medicare and commercial payers under neuro-muscular re-education.

    • Less than $1M annual revenues
    • 1-10 employees
    • $2.5M raised in May, 2019
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  132. people having meeting on rectangular brown table


  133. WhizAI ($1M to $10M)

    WhizAI is the first and only purpose-built cognitive insights platform for life sciences, empowering users to get answers to their business questions by simply asking via voice, text on web and mobile. WhizAI is trained on life sciences data [867, IQVIA, CTMS, and APLD] and business terminologies [NRx, TRx, PBMs, Plans, TAs, etc.], enabling it to answer even the most complex questions from billions of records in seconds. Fast, easy, and scalable, WhizAI is the trusted partner of choice at the top global life sciences companies. Asked. Answered. Instantly. Simply ask a question about sales, market access, patient services, or clinical trials -- and WhizAI answers it instantly. WhizAI's conversational interface allows users to simply talk to the enterprise data giving them complete autonomy to drill into every level of details along with real-time updates. WhizAI’s advanced machine learning algorithms scan entire data to deliver proactive alerts and automatically surface anomalies, easily pinpointing stagnating sales, market share changes, patient drop-offs and much more. WhizAI enjoys a 100% adoption by all business users, contributes to 60% reduction in calls to IT and 50% reduction in operational overheads within first few months of implementation for enterprise pharmaceuticals.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $4M raised in July, 2020
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  134. three women sitting around table using laptops


  135. TYME Inc ($1M to $10M)

    TYME Inc. is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have tolerable toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic requirements to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s immune system.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $100M raised in February, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  136. photo of industrial machines near table


  137. Vyteris ($10M to $50M)

    Vyteris is the maker of the first active drug delivery patch to receive market approval from the U.S. Food and Drug Administration (FDA). Vyteris was organized in November 2000 as a spinout of the Transdermal Systems unit of Becton Dickinson and Company (BD), to develop, manufacture, and commercialize pharmaceutical products based upon this unique, advanced drug delivery technology. BD created Transdermal Systems just prior to 1990 and invested 10 years and close to $80 million in developing the basis of the Vyteris transdermal drug delivery system.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $0.1M raised in July, 2011
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  138. group of people sitting beside rectangular wooden table with laptops